Literature DB >> 11980131

[Hypotensive effect of long-acting garlic tablets allicor (a double-blind placebo-controlled trial)].

I V Andrianova, I V Fomchenkov, A N Orekhov.   

Abstract

AIM: To evaluate a hypotensive action of long-acting garlic powder tablets allicor in patients with mild or moderate hypertension and to compare allicor effects with those of foreign analog--kwai garlic tablets.
MATERIAL AND METHODS: A double-blind, randomized and placebo-controlled study enrolled 85 patients with mild or moderate hypertension. The patients were divided into 4 groups: group 1 received allicor in a dose 600 mg/day, group 2--2400 mg/day, group 3--kwai in a dose 900 mg/day, group 4--placebo.
RESULTS: Allicor produced reaction in both systolic and diastolic pressure. An increase of allicor daily dose to 2400 mg does not provide an additional hypotensive effect. Kwai results in only systolic but not diastolic arterial pressure lowering.
CONCLUSION: Allicor is more effective than kwai in reduction of diastolic blood pressure. It can be recommended as a hypotensive treatment in mild and moderate arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980131

Source DB:  PubMed          Journal:  Ter Arkh        ISSN: 0040-3660            Impact factor:   0.467


  3 in total

1.  The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease.

Authors:  Igor A Sobenin; Valentin V Pryanishnikov; Lyudmila M Kunnova; Yevgeny A Rabinovich; Danik M Martirosyan; Alexander N Orekhov
Journal:  Lipids Health Dis       Date:  2010-10-19       Impact factor: 3.876

2.  A review of studies of garlic (Allium sativum) on serum lipids and blood pressure before and after 1994: does the amount of allicin released from garlic powder tablets play a role?

Authors:  Marc P McRae
Journal:  J Chiropr Med       Date:  2005

Review 3.  Effect of garlic on blood pressure: a systematic review and meta-analysis.

Authors:  Karin Ried; Oliver R Frank; Nigel P Stocks; Peter Fakler; Thomas Sullivan
Journal:  BMC Cardiovasc Disord       Date:  2008-06-16       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.